Head-to-head evidence
Clobazam (Onfi) vs Ganaxolone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Clobazam (Onfi)
Marketed by Lundbeck LLC and partners
NCT00518713 · Phase 3 · completed
The study randomly assigned 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators masked to treatment. Its clinical primary endpoint—percent reduction in drop seizures—was statistically better than placebo for all three doses, supporting a strong evidence grade.
Ganaxolone
Marketed by Immedica Pharma AB
NCT01963208 · Phase 3 · completed
The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clobazam (Onfi)'s landscape · Ganaxolone's landscape